Blinatumumab is a bispecific antibody that simultaneously targets the CD3 receptor on T cells and CD19 on B cells. Blinatumumab is approved for the treatment of acute lymphocytic leukemia (ALL) both in children and in adults.
The drug is administered intravenously as a continuous infusion in increased doses.
My questions:
- How do you apply the medication: via the PORT, via a CVC or Peripheral?
- In our Zenter, we started administering the drug via the PORT. But the blood flows back in the port needle in infusion-system to the filter and stops the infusion of Blanitumumab!!. Have you had such problems? What could be the solution?
- Badges
- Science topic
More Hosam Ghanem's questions See All
Similar questions and discussions